Viread Tablets (Tenofovir Disoproxil Fumarate)

Adult dose

Adults For the treatment of HIV-1 or chronic hepatitis B, take 1 tablet (300mg) once daily. It may be taken with or without food. The optimal duration of treatment for chronic hepatitis B is unknown. Patients with renal impairment For patients with baseline creatinine clearance <50mL/min, adjust the dosing interval of this medicine according to Table 1. Creatinine clearance (mL/min)a ≥50: every 24 hours Creatinine clearance (mL/min)a 30-49: every 48 hours Creatinine clearance (mL/min)a 10-29: every 72-96 hours Patients on hemodialysis: every 7 days or approximately 12 hours after the total dialysis sessionb a. Calculated using ideal (lean) body weight. b. Administer once weekly, assuming 3 hemodialysis sessions of approximately 4 hours each per week. This medicine should be administered after dialysis is completed. No adjustment to the dosing interval is necessary in patients with mild renal impairment (creatinine clearance 50-80mL/min). There are no dosing recommendations for patients with creatinine clearance below 10mL/min who are not receiving hemodialysis.

Child dose

Children aged 12 years and older (35kg or more): For the treatment of HIV-1 or chronic hepatitis B, take 1 tablet (300mg) once daily. It may be taken with or without food. Children with chronic hepatitis B who weigh less than 35kg: Safety and efficacy have not been established. Pediatric patients with renal impairment: There are no data to support dosage recommendations.

This medication is used to treat hepatitis B virus; abrupt discontinuation may lead to a severe worsening of hepatitis, so caution is required. Individuals allergic to this medication or sensitive to any of its components should not take it. Patients with lactose intolerance or certain genetic metabolic disorders should not use this medication. This medication should not be used in conjunction with other tenofovir-containing drugs or adefovir preparations. Patients with impaired kidney function should undergo renal function tests before taking this medication, and renal function should be monitored periodically during treatment. Particularly, caution is warranted when taken with drugs that may burden the kidneys, as there is an increased risk of kidney damage. This medication may also impact bone health, so patients at risk of osteoporosis or fractures should consider bone density tests. If pain in bones or muscles persists during treatment, consult a healthcare provider immediately. This medication should be used in conjunction with other appropriate treatments for patients co-infected with HIV and hepatitis B, and HIV testing is recommended before treatment. Pregnant women can use this medication safely; however, they must consult a physician before taking it. Nursing mothers should avoid breastfeeding, as the components of this medication can be transferred to breast milk. Special caution is required when giving this medication to children and the elderly, especially as the safety and efficacy have not been established in children under 12 years of age. In cases of overdose, seek immediate medical treatment; this medication can be partially removed through hemodialysis. When storing this medication, keep it in a sealed container to protect it from air and moisture, store at room temperature between 1°C and 30°C, out of reach of children, and keep it in its original container.

• Worsening of hepatitis
• acute kidney failure
• Fanconi syndrome
• hypophosphatemia
• renal impairment
• bone pain
• limb pain
• fractures
• muscle pain
• proximal tubular disorder

This medication must be stored in a tightly sealed container to protect it from air and moisture. The recommended storage temperature is room temperature between 1°C and 30°C. Storing it this way helps to safely maintain its effectiveness.

Appearance

Pale blue almond-shaped film-coated tablets

Package unit

30 tablets/bottle